We are happy to see that Nanolive imaging has been used to confirm the success of another new therapy, this time treating melasma. In their latest paper “Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology”, mesoestetic’s Biotechnology Unit published Nanolive refractive index images of treated and untreated melanocytes1.
Thanks to the high refractive index values of melanin granules, they could be clearly imaged label-free, using the Nanolive platform. Indeed, the images clearly showed that mesoestetic’s treatment decreased the number of melanin granules in melanocytes, which will translate to decreased pigmentation of melasmas in patient skin.
“Nanolive technology has been very useful in order to study the effect of our compounds on melanocytes with high resolution. Live-cell imaging allowed us to see how morphology and melanosomes accumulation changed in real time with the treatment, providing clear evidence of the in vitro efficacy of these compounds.”
Mesoestetic is a pharmaceutical company leading the development and production of therapies in dermatology and aesthetic medicine. You can read their paper in full here.
References:
(1) Alfredo, M.-G.; Maribel, P.-M.; Eloy, P.-R.; Susana, G.-E.; Shotze, L. G.; Carmen, G. M. Depigmenting Topical Therapy Based on a Synergistic Combination of Compounds Targeting the Key Pathways Involved in Melasma Pathophysiology. Experimental Dermatology. https://doi.org/10.1111/exd.14752 .
Read our latest news
Nanolive at the SPS Annual Meeting September 18-20
Joint presentation with Sanofi Nanolive is delighted to invite for you to attend our upcoming joint presentation with Sanofi at the Safety Pharmacology Society (SPS) Annual Meeting in Brussels on September 20, 2023, from 12:30 PM to 1:30 PM in Studio 214. During our...
Webinar – High content in vitro imaging for translational success: targeted therapies
Nanolive hosts this event on "Non-invasive, high content live cell assays to increase translational relevance of in vitro drug development of biologics and small molecules". In this webinar, we present the following use-cases of our immuno-oncology and cytotoxicity...
Nanolive empowers groundbreaking ferroptosis research published in Nature
Congratulations to the Conrad lab for their latest Nature paper 'Phase separation of FSP1 promotes ferroptosis'! This beautiful capture published as part of the paper provides new information about the events leading up to ferroptotic cell death. Using refractive...
